Greenwich LifeSciences Inc. is a clinical-stage biopharmaceutical company that focuses on developing immunotherapy for the treatment of breast cancer. The company was founded in 2006 and is headquartered in Stafford, Texas.
Greenwich LifeSciences is dedicated to addressing the unmet medical needs of women diagnosed with breast cancer by developing immunotherapy treatments. Their lead product candidate, GP2, is a novel immune system activating protein that targets HER2/neu-expressing breast cancer cells.
In 2020, the company completed its initial public offering (IPO) on the Nasdaq stock exchange under the ticker symbol GLSI. The IPO raised approximately $40 million, which was used to fund the clinical development of GP2.
Greenwich LifeSciences has received fast track designation from the US Food and Drug Administration (FDA) for the GP2 immunotherapy treatment. Fast track designation is given to treatments that address a significant unmet medical need, and are designed to expedite the development and review process.
As of May 2021, Greenwich LifeSciences is conducting a Phase III clinical trial of the GP2 immunotherapy treatment. The trial is designed to evaluate the efficacy and safety of the treatment in preventing breast cancer recurrence in HER2/neu overexpressing breast cancer patients. If the trial is successful, GP2 has the potential to become a significant breakthrough in the treatment of breast cancer, improving patient outcomes and quality of life.